A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
Plain-language summary
This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
tislezumab (DRUG): Tislelizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks (Q3W). | golidocitinib (DRUG): Golidocitinib: Dose-escalating oral regimens: Dose level A: 150 mg every other day (QOD). Dose level B: 150 mg once daily (QD). | Selinexor (DRUG): Selinexor: Dose-escalating oral regimens: Dose A: 40 mg once weekly (QW) . Dose B: 60 mg QW for 2 consecutive weeks, followed by 1 week off.
tislezumab, golidocitinib, Selinexor
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details